Who is sponsoring NCT05921903?

NCT05921903 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT05921903?

Interventions in NCT05921903: RSVPreF3 OA Investigational Vaccine.

What condition does NCT05921903 study?

NCT05921903 studies Respiratory Syncytial Virus Infections.

Is NCT05921903 still recruiting?

NCT05921903 is currently completed. Last updated 8 August 2025.

Are results published for NCT05921903?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-08-08 · How we verify

NCT05921903: RSV OA=ADJ-023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

Completed Phase 2 Results posted Last updated 8 August 2025

What this trial tests

Phase 2 trial testing RSVPreF3 OA Investigational Vaccine in Respiratory Syncytial Virus Infections in 386 participants. Completed in 16 May 2025.

Timeline

28 July 2023

Primary endpoint
25 June 2024

16 May 2025

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	386
Start date	28 July 2023
Primary completion	25 June 2024
Estimated completion	16 May 2025
Sites	46 locations across Italy, Japan, Germany, South Korea, Canada, Australia, United States, Spain

Drugs / interventions tested

RSVPreF3 OA Investigational Vaccine — full drug profile →

Conditions studied

Respiratory Syncytial Virus Infections — all drugs for Respiratory Syncytial Virus Infections →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Respiratory Syncytial Virus Infections. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group Primary · At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)

MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-A post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).

Group	Value	95% CI
RSV_IC_2 Group	1.34	1.20 – 1.48

RSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group Primary · At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)

MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-B post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).

Group	Value	95% CI
RSV_IC_2 Group	1.26	1.14 – 1.40

RSV-A And RSV-B Serum Neutralizing Titers Expressed As Geometric Mean Titers (GMT) for RSV_IC_1, RSV_IC_2 and RSV_HA Groups Secondary · At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 in a subset of participants (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days) and Visit 4 (Visit 3 + 30-42 days)

Neutralizing titers were calculated as GMT and expressed in titers (Estimated Dilution 60 \[ED60\]).

RSV-A , Visit 1

Group	Value	95% CI
RSV_IC_1 Group	807.0	700.9 – 929.2
RSV_IC_2 Group	814.1	701.3 – 945.1
RSV_HA Group	889.0	781.9 – 1010.6

RSV-A , Visit 2

Group	Value	95% CI
RSV_IC_1 Group	1775.8	1201.0 – 2625.6
RSV_IC_2 Group	2031.1	1283.6 – 3213.9
RSV_HA Group	6716.8	4907.6 – 9193.0

RSV-A , Visit 3

Group	Value	95% CI
RSV_IC_1 Group	3990.8	3219.4 – 4947.0
RSV_IC_2 Group	4174.0	3230.7 – 5392.6
RSV_HA Group	6822.5	5926.2 – 7854.4

RSV-A , Visit 4

Group	Value	95% CI
RSV_IC_1 Group	4184.7	3360.1 – 5211.7
RSV_IC_2 Group	5377.9	4265.4 – 6780.6
RSV_HA Group	5707.0	4853.6 – 6710.3

RSV-B, Visit 1

Group	Value	95% CI
RSV_IC_1 Group	864.2	727.8 – 1026.2
RSV_IC_2 Group	892.9	754.1 – 1057.3
RSV_HA Group	1027.3	889.6 – 1186.3

RSV-B, Visit 2

Group	Value	95% CI
RSV_IC_1 Group	2325.3	1592.9 – 3394.5
RSV_IC_2 Group	2603.1	1714.9 – 3951.3
RSV_HA Group	8113.6	5699.9 – 11549.5

RSV-B, Visit 3

Group	Value	95% CI
RSV_IC_1 Group	5002.9	3901.7 – 6414.8
RSV_IC_2 Group	4834.7	3736.6 – 6255.6
RSV_HA Group	9140.5	7805.3 – 10704.1

RSV-B, Visit 4

Group	Value	95% CI
RSV_IC_1 Group	4461.7	3519.0 – 5657.0
RSV_IC_2 Group	5820.8	4658.2 – 7273.5
RSV_HA Group	6281.6	5377.6 – 7337.7

RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups Secondary · At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)

Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Visit 2

Group	Value	95% CI
RSV_HA Group	6689.9	4639.3 – 9646.7
Pooled RSV_IC Group	1902.8	1479.6 – 2446.9

Visit 3

Group	Value	95% CI
RSV_HA Group	6653.8	5503.5 – 8044.6
Pooled RSV_IC Group	4113.0	3595.5 – 4705.0

RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups Secondary · At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)

Group GMT of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Group	Value	95% CI
RSV_IC_1 Group	4041.9	3254.8 – 5019.3
RSV_IC_2 Group	5098.4	4088.8 – 6357.3

RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups Secondary · At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)

Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Group	Value	95% CI
RSV_IC_1 Group	4244.8	3551.8 – 5073.0
RSV_HA Group	5541.6	4622.0 – 6644.2

RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups Secondary · At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)

Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Group	Value	95% CI
RSV_IC_2 Group	5505.3	4627.0 – 6550.3
RSV_HA Group	5615.7	4719.8 – 6681.6

RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups Secondary · At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)

Group GMT was assessed for RSV\_HA group over pooled RSV\_IC group (combined RSV\_IC\_1 and RSV\_IC\_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_HA and Pooled RSV\_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Visit 2

Group	Value	95% CI
RSV_HA Group	8238.7	5972.9 – 11364.1
Pooled RSV_IC Group	2442.6	1958.3 – 3046.7

Visit 3

Group	Value	95% CI
RSV_HA Group	8545.5	7031.3 – 10385.8
Pooled RSV_IC Group	5106.9	4448.4 – 5863.0

RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups Secondary · At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)

Group GMT ratio of RSV\_IC\_2 over RSV\_IC\_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_IC\_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Group	Value	95% CI
RSV_IC_1 Group	4333.3	3510.0 – 5349.8
RSV_IC_2 Group	5550.5	4478.3 – 6879.4

RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups Secondary · At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)

Group GMT of RSV\_HA over RSV\_IC\_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_1 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Group	Value	95% CI
RSV_IC_1 Group	4632.9	3890.8 – 5516.6
RSV_HA Group	5973.5	5000.9 – 7135.4

RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups Secondary · At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)

Group GMT of RSV\_HA over RSV\_IC\_2 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV\_IC\_2 and RSV\_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.

Group	Value	95% CI
RSV_IC_2 Group	6090.6	5184.6 – 7155.0
RSV_HA Group	6123.0	5212.1 – 7193.0

RSV-A And RSV-B Serum Neutralizing Titers Expressed As MGI Secondary · At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days), Visit 3 (Visit 1 + 30-60 days) and Visit 4 (Visit 3 + 30-42 days), each compared to Visit 1 (Day 1)

MGI was assessed at Visit 2 (in a subset of participants) over Visit 1 and Visit 3 over Visit 1 in RSV\_HA and pooled RSV\_IC (combined RSV\_IC\_1 and RSV\_IC\_2 groups), and at Visit 4 over Visit 1 in RSV\_IC\_1, RSV\_IC\_2, RSV\_HA groups.

RSV-A, Visit 2

Group	Value	95% CI
RSV_IC_1 Group	2.14	1.44 – 3.18
RSV_IC_2 Group	2.20	1.45 – 3.34
RSV_HA Group	7.59	5.44 – 10.58
Pooled RSV_IC Group	2.17	1.64 – 2.87

RSV-A, Visit 3

Group	Value	95% CI
RSV_IC_1 Group	4.92	3.95 – 6.12
RSV_IC_2 Group	5.01	4.00 – 6.27
RSV_HA Group	7.82	6.74 – 9.06
Pooled RSV_IC Group	4.96	4.24 – 5.80

RSV-A, Visit 4

Group	Value	95% CI
RSV_IC_1 Group	5.29	4.24 – 6.60
RSV_IC_2 Group	6.53	5.32 – 8.01
RSV_HA Group	6.55	5.60 – 7.6

RSV-B, Visit 2

Group	Value	95% CI
RSV_IC_1 Group	2.51	1.78 – 3.55
RSV_IC_2 Group	2.54	1.75 – 3.67
RSV_HA Group	8.59	6.59 – 11.20
Pooled RSV_IC Group	2.53	1.98 – 3.23

RSV-B, Visit 3

Group	Value	95% CI
RSV_IC_1 Group	5.72	4.53 – 7.21
RSV_IC_2 Group	5.34	4.25 – 6.72
RSV_HA Group	8.80	7.67 – 10.11
Pooled RSV_IC Group	5.53	4.71 – 6.51

RSV-B, Visit 4

Group	Value	95% CI
RSV_IC_1 Group	5.22	4.20 – 6.49
RSV_IC_2 Group	6.52	5.34 – 7.97
RSV_HA Group	6.35	5.50 – 7.33

Adverse events — posted to ClinicalTrials.gov

Time frame: Solicited AEs: within 7 days post each dose administration, and unsolicited AEs: within 30 days post each dose administration, where doses were administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1(Day 1) + 30-60 days] for RSV_IC_2 group). SAEs, related SAEs, fatal SAEs, pIMDs, related pIMDs and AESIs specific for renal/lung transplant: Visit 1 (Day 1) to Visit 4 (Visit 3 + 30-42 days).. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

RSV_IC_1 Group

Serious: 12/131 (9%)

Deaths: 0/131

RSV_IC_2 Group

Serious: 18/130 (14%)

Deaths: 2/130

RSV_HA Group

Serious: 3/125 (2%)

Deaths: 0/125

Serious adverse events (36 terms)

Reaction	System	RSV_IC_1 Group	RSV_IC_2 Group	RSV_HA Group
Pneumonia	Infections and infestations	—	—	—
Sepsis	Infections and infestations	—	—	—
Gastroenteritis	Infections and infestations	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—
Pyrexia	General disorders	—	—	—
COVID-19	Infections and infestations	—	—	—
Urinary tract infection	Infections and infestations	—	—	—
Aspergillus infection	Infections and infestations	—	—	—
Urosepsis	Infections and infestations	—	—	—
Escherichia bacteraemia	Infections and infestations	—	—	—
Gangrene	Infections and infestations	—	—	—
Bursitis infective	Infections and infestations	—	—	—
Gastroenteritis Escherichia coli	Infections and infestations	—	—	—
Influenza	Infections and infestations	—	—	—
Oesophageal candidiasis	Infections and infestations	—	—	—
Colitis	Gastrointestinal disorders	—	—	—
Invasive ductal breast carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—
Oropharyngeal squamous cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—
Small cell lung cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—
Lung adenocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—
Myelodysplastic syndrome with excess blasts	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—
Renal impairment	Renal and urinary disorders	—	—	—
Urinary retention	Renal and urinary disorders	—	—	—
Chest pain	General disorders	—	—	—
Acute respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—

Other adverse events (113 terms — click to expand)

Reaction	System	RSV_IC_1 Group	RSV_IC_2 Group	RSV_HA Group
Administration site pain	General disorders	—	—	—
Fatigue	General disorders	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—
Headache	Nervous system disorders	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—
Administration site erythema	General disorders	—	—	—
Administration site swelling	General disorders	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Dizziness	Nervous system disorders	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—
Administration site pruritus	General disorders	—	—	—
Oedema peripheral	General disorders	—	—	—
Chills	General disorders	—	—	—
Pyrexia	General disorders	—	—	—
Neck pain	Musculoskeletal and connective tissue disorders	—	—	—
COVID-19	Infections and infestations	—	—	—
Urinary tract infection	Infections and infestations	—	—	—
Sinusitis	Infections and infestations	—	—	—
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	—	—	—
Productive cough	Respiratory, thoracic and mediastinal disorders	—	—	—
Chest pain	General disorders	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—
Gastroenteritis	Infections and infestations	—	—	—
Bronchitis	Infections and infestations	—	—	—
Lymph gland infection	Infections and infestations	—	—	—
Rhinitis	Infections and infestations	—	—	—
Cystitis	Infections and infestations	—	—	—
Enterococcal infection	Infections and infestations	—	—	—
Escherichia urinary tract infection	Infections and infestations	—	—	—
Herpes simplex reactivation	Infections and infestations	—	—	—
Pneumonia pseudomonal	Infections and infestations	—	—	—
Stenotrophomonas maltophilia pneumonia	Infections and infestations	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—
Clostridium difficile colitis	Infections and infestations	—	—	—
Gingivitis	Infections and infestations	—	—	—

Most-reported serious reactions: Pneumonia, Sepsis, Gastroenteritis, Acute kidney injury, Pyrexia, COVID-19, Urinary tract infection, Aspergillus infection.

Data from ClinicalTrials.gov NCT05921903 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune response.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
Terstappen J, Hak SF, Bhan A, Bogaert D, et al · · 2024 · cited 54× · PMID 39326422 · DOI 10.1016/s1473-3099(24)00455-9
Global progress in clinical research on human respiratory syncytial virus vaccines.
Peng R, Chen C, Chen Q, Zhang Y, et al · · 2024 · cited 8× · PMID 39286350 · DOI 10.3389/fmicb.2024.1457703
Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age.
Papazisis G, Topalidou X, Gioula G, González PA, et al · · 2024 · cited 8× · PMID 38675736 · DOI 10.3390/vaccines12040353
Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned.
Brüssow H. · · 2025 · cited 3× · PMID 40420998 · DOI 10.1093/femsml/uqaf003
Recent advances in the prevention and treatment of respiratory syncytial virus disease.
Sanchez-Martinez A, Moore T, Freitas TS, Benzaken TR, et al · · 2025 · cited 3× · PMID 40202895 · DOI 10.1099/jgv.0.002095
Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control.
Shi J, Huang X, Ye C, Lu Y, et al · · 2026 · PMID 41261734 · DOI 10.1002/med.70025
Could more adults than just those aged 75-79 years potentially benefit from vaccination against RSV: insights from UK data.
Vyse A, Hockey C, Wright H, Ellsbury G. · · 2025 · PMID 41199924 · DOI 10.1080/20523211.2025.2576618
Immune persistence and safety of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, et al · · 2025 · PMID 41194599 · DOI 10.1080/21645515.2025.2579335

Verify or expand the search:

Other recruiting trials for Respiratory Syncytial Virus Infections

Currently open trials in the same condition.

NCT07214571 — A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of · Phase 2 · recruiting
NCT07220109 — A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 5 · Phase 3 · recruiting
NCT07239583 — Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) · recruiting
NCT07092865 — A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and th · Phase 2 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05921903 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 8 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05921903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing